Cupido 75 mg is an oral, prescription-only antiplatelet medication formulated to prevent atherothrombotic events in high-risk adult cardiovascular patients. Containing Clopidogrel (as bisulfate), Cupido acts directly on blood platelets to inhibit aggregation, thereby reducing the formation of intra-arterial blood clots (thrombi).
It is clinically indicated for secondary prevention in patients with a history of recent myocardial infarction (heart attack), recent ischemic stroke, or established peripheral arterial disease (PAD). Additionally, Cupido 75 mg is prescribed in combination with acetylsalicylic acid (aspirin) for patients experiencing acute coronary syndrome (ACS), including non-ST-segment elevation ACS (unstable angina/NSTEMI) and ST-segment elevation myocardial infarction (STEMI), as well as those undergoing percutaneous coronary intervention (PCI) with stent placement.
Active Ingredient & Pharmacological Mechanism
Active Ingredient
Clopidogrel (75 mg per tablet): A thienopyridine-class prodrug that undergoes hepatic biotransformation to produce its active metabolite.
Mechanism of Action
Irreversible P2Y12 Receptor Blockade: The active metabolite of clopidogrel selectively and irreversibly binds to the adenosine diphosphate (ADP) P2Y12 receptor on the surface of human blood platelets.
Inhibition of Platelet Activation: By preventing ADP binding, clopidogrel inhibits subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, which is the primary pathway for fibrinogen binding and cross-linking between platelets.
Long-Lasting Anti-Aggregatory Effect: Because the receptor binding is irreversible, affected platelets remain inhibited for the remainder of their natural lifespan (approximately 7 to 10 days). Platelet function gradually returns to baseline as new platelets are released by the bone marrow.
Key Clinical Indications & Health Benefits
Prevention of Ischemic Stroke & Re-Infarction: Inhibits arterial clot formation, lowering the incidence of recurrent thromboembolic events in patients with vascular disease.
Post-PCI & Stent Thrombosis Prophylaxis: Reduces the risk of acute, subacute, and late stent thrombosis in patients undergoing coronary artery stenting when co-administered with aspirin.
Management of Peripheral Arterial Disease (PAD): Improves systemic circulation safety by reducing cardiovascular mortality and ischemic complications in patients with symptomatic lower extremity artery disease.
Usage Instructions & Administration Guidelines
Important: Cupido 75 mg must be taken strictly under medical supervision. The dosage regimen depends on the specific cardiovascular condition being treated.
Standard Maintenance Dose: The usual clinical dosage is one tablet (75 mg) once daily.
Loading Dose (When Indicated): In acute coronary syndrome (ACS) management or post-stenting, a single initiating loading dose (e.g., 300 mg) may be administered under direct clinical guidance prior to switching to daily 75 mg maintenance therapy.
Administration: Tablets should be swallowed whole with fluid, with or without food. Consistent daily administration at the same time helps maintain steady therapeutic plasma levels.
Duration of Therapy: The length of treatment is determined by the treating physician based on clinical guidelines and individual cardiovascular risk factors.
Safety Precautions, Contraindications & Interactions
Absolute Contraindications
Active Pathological Bleeding: Contraindicated in patients with ongoing bleeding disorders, such as active peptic ulcer disease, intracranial hemorrhage, or hemophilia.
Severe Hepatic Impairment: Not recommended for patients with severe liver dysfunction due to altered drug metabolism and elevated risk of bleeding diathesis.
Hypersensitivity: Known allergy or severe reaction to Clopidogrel or any inactive tablet excipients.
Clinical Warnings & Safety Precautions
Bleeding Risk: Due to its antiplatelet effect, Cupido increases the duration of bleeding. Patients should report unusual bruising, black or tarry stools, red urine, or prolonged nosebleeds to their physician immediately.
Surgical Interventions: Cupido 75 mg should be discontinued 5 to 7 days prior to elective surgery or invasive dental procedures to allow platelet aggregation to recover and minimize perioperative hemorrhage risk. Resume therapy only when adequate hemostasis is restored.
CYP2C19 Interactions: Clopidogrel relies on the hepatic enzyme CYP2C19 for conversion to its active metabolite. Concomitant use with strong or moderate CYP2C19 inhibitors—such as Omeprazole or Esomeprazole—significantly decreases active metabolite levels and efficacy. Alternative acid-suppressive agents (e.g., pantoprazole, H2-blockers) should be evaluated if gastroprotection is required.
Pregnancy & Lactation: Use during pregnancy or breastfeeding requires careful risk-benefit evaluation by a cardiologist, as adequate controlled human safety data are limited.
Storage & Product Specifications
Dosage Form: Film-coated tablets.
Packaging Size: 30 tablets per box (blister packaging).
Storage Conditions: Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Medication
